Recently, a successful clinical trial reported that when compared with placebo, Vericiguat, a novel oral sGC stimulator, significantly reduced the incidence of cardiovascular death and hospitalization for heart failure (HF) in patients with worsening HF with reduced ejection fraction (HFrEF) [35]. This evidence concerns the gene SGCB and heart failure.